ReviewExpert reviews in molecular medicine2009
Cholangiocyte proliferation and liver fibrosis.
Review in Expert reviews in molecular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 1 synthesis or guideline pooled it, 200 citations in OpenAlex.
- Wisteria floribunda agglutinin-positive Mac-2-binding protein as a diagnostic biomarker in liver cirrhosis: an updated meta-analysis.Scientific reports · 2020Pooled it
- Single-nucleus chromatin landscapes of cholestatic injury and repair in mice liver.Scientific data · 2026Article
- Key genes and histopathological alterations in hepatic fibrogenesis after segmental cholestasis in weaned rats.Pediatric research · 2026Article
- Evaluation of Five Plasma miRNAs as Biomarkers for Minimally Invasive Staging of Liver Fibrosis in β-Thalassaemia Patients.International journal of molecular sciences · 2025Article
- Cell-Type Deconvolution Reveals Dynamic Changes in MASLD.Liver international communications · 2025Article
- Single-cell transcription reveals hepatocyte-to-cholangiocyte reprogramming and biliary gene profile in biliary atresia.Hepatology communications · 2025Article
- Chemogenomic Screening in a Patient-Derived 3D Fatty Liver Disease Model Reveals the CHRM1-TRPM8 Axis as a Novel Module for Targeted Intervention.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis.Clinical and molecular hepatology · 2024Article
- The inhibition of YAP Signaling Prevents Chronic Biliary Fibrosis in the Abcb4Aging and disease · 2024Article
- Advancing vaccine development againstFrontiers in pharmacology · 2024Review
- VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis.Cell stem cell · 2023Article
- An optimized visualization and quantitative protocol for in-depth evaluation of lymphatic vessel architecture in the liver.American journal of physiology. Gastrointestinal and liver physiology · 2023Article
- Article
- Update on Hepatobiliary Plasticity.Seminars in liver disease · 2023Article
- Liver secretin receptor predicts portoenterostomy outcomes and liver injury in biliary atresia.Scientific reports · 2022Article
- Article
- Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis.Nature communications · 2022Article
- Increased Hepatic Expression of SARS-CoV-2 Entry Points and Proinflammatory Cytokines in Cirrhosis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Article
- Extracellular vesicles: catching the light of intercellular communication in fibrotic liver diseases.Theranostics · 2022Review
- Generation of functional ciliated cholangiocytes from human pluripotent stem cells.Nature communications · 2021Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Cholangiocyte proliferation is triggered during extrahepatic bile duct obstruction induced by bile duct ligation, which is a common in vivo model used for the study of cholangiocyte proliferation and liver fibrosis. The proliferative response of cholangiocytes during cholestasis is regulated by the complex interaction of several factors, including gastrointestinal hormones, neuroendocrine hormones and autocrine or paracrine signalling mechanisms. Activation of biliary proliferation (ductular reaction) is thought to have a key role in the initiation and progression of liver fibrosis. The first part of this review provides an overview of the primary functions of cholangiocytes in terms of secretin-stimulated bicarbonate secretion--a functional index of cholangiocyte growth. In the second section, we explore the important regulators, both inhibitory and stimulatory, that regulate the cholangiocyte proliferative response during cholestasis. We discuss the role of proliferating cholangiocytes in the induction of fibrosis either directly via epithelial mesenchymal transition or indirectly via the activation of other liver cell types. The possibility of targeting cholangiocyte proliferation as potential therapy for reducing and/or preventing liver fibrosis, and future avenues for research into how cholangiocytes participate in the process of liver fibrogenesis are described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.